System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Lawrence A Leiter, MD is an expert in Cardiology at St. Michael's Hospital (Canada). As of October 2026, ScienceLeadR ranks Lawrence A Leiter in the top 1% of experts worldwide for Dyslipidemias, Hypercholesterolemia and Lipid Metabolism Disorders. Lawrence A Leiter has authored 892 publications, the most recent in 2026, and is an investigator in 88 clinical trials, 2 of them ongoing. SLR score: 3,089 (community average: 125). How the SLR is computed.

LeadR Profile

Lawrence A Leiter, MD St. Michael's Hospital Canada
3 089 ScienceLeadR Reputation 3089

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Endocrinology - Nutrition

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1985 - 2026
Source: PubMed

Unity Health Toronto

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 892

Citations

Citations: 116 999 1st author: 89 Last author: 90 Unique author: 19

Main journals

Can J Cardiol 75
Circulation 59
Diabetes Care 51
Can J Diabetes 45
Diabetes Obes Metab 41

Best Journals

N Engl J Med 33
Eur Heart J 13
Circulation 11

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Benefit of Sotagliflozin Across the Full Range of Baseline Blood Pressure in the SOLOIST-WHF Trial.
PMID 42670741 — blood, heart failure, blood pressure		JACC Heart Fail20260
Cumulative Benefit With Evolocumab in Patients With No Prior Myocardial Infarction or Stroke in the VESALIUS-CV Study.
PMID 42663360 — stroke, myocardial infarction, incidence, lipoproteins, cardiology, cholesterol, atherosclerosis, lipoproteins, ldl, ischemia		J Am Coll Cardiol20261
Evolocumab and risk of first myocardial infarction: the VESALIUS-CV trial.
PMID 42663056 — myocardial infarction, cardiology		Eur Heart J Top journal20260
Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.
PMID 42333640 — heart diseases, cholesterol, ldl, safety, lipoproteins, c-reactive protein, myalgia, aged, cholesterol, hydroxymethylglutaryl-coa reductase inhibitors		J Am Heart Assoc20260
Efficacy of phytosterols for reduction of cardiometabolic risk factors: An umbrella review of systematic reviews and meta-analyses and updated dose-response meta-analyses of randomized trials.
PMID 42275989 — cholesterol, ldl, phytosterols, blood, cardiometabolic risk factors, blood pressure, sterols, adiposity, cholesterol, parenteral nutrition, risk factors, triglycerides, enteral nutrition		Clin Nutr20263

Clinical Studies 88

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 43
N/A 24
Phase 4 11
Phase 2 10

By status:

Completed 64
Unknown 15
Terminated 6
Active not recruiting 3

By type:

Interventional 71
Observational 17

By Monocentric/Multicentric:

monocentric 31
multicentric2to4 8
multicentric5to9 5
multicentricup10 44

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
SRMA of the Effect of Soy Milk vs Cow s Milk on Cardiometabolic Outcomes
NCT05637866 — liver diseases, hemoglobins, fasting, milk, body mass index, insulin, blood, metabolic diseases, non-alcoholic fatty liver disease, cardiovascular diseases, blood pressure, sugars, classification, lactose, lipid metabolism disorders, liver, adiposity, alcoholics, food, cholesterol, soy milk, body weight, sucrose, waist circumference, beverages, fatty liver, triglycerides, apolipoproteins, fatty liver, alcoholic, plasma, food, processed, lipids		N/AActive not recruiting2022
The Soy Treatment Evaluation for Metabolic Health (STEM) Trial
NCT05191160 — diabetes mellitus, hypertension, milk, heart diseases, whey proteins, microscopy, electron, scanning transmission, heart, cardiovascular diseases, dyslipidemias, sugars, public health, liver, prediabetic state, sugar-sweetened beverages, soy milk, obesity, metabolically benign, obesity, risk factors, grassland, therapeutics, overweight, whey, beverages, heart disease risk factors, pharmaceutical vehicles, metabolic syndrome, epidemics, caseins		N/AActive not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS